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Background: Corticosteroid or intravenous immunoglobulin is used in the management of idiopathic
thrombocytopenic purpura during pregnancy.
Case presentation: A patient with idiopathic thrombocytopenic purpura had a previous history of interrupted
pregnancy due to severe thrombocytopenia, and was unresponsive to high doses of corticosteroids and
intravenous immunoglobulin. Immediately following pregnancy, our patient had a marked elevation in plasma
levels of fibrinogen degradation products, D-dimer, and platelet factor 4, with a decrease in platelets, suggesting
platelet activation and thrombogenesis. Combined treatment with an anticoagulant agent could prevent exacerbation
of thrombocytopenia throughout pregnancy. Although the underlying causes leading to the series in her pregnancy
course were uncertain, there were notable serological abnormalities, such as weakly positive antinuclear antibody and
anti-U1-RNP antibody.
Conclusion: When thrombocytopenia rapidly develops in patients with idiopathic thrombocytopenic purpura
immediately following pregnancy, the possibility of a thrombogenic state and differential diagnosis, including
antiphospholipid syndrome and collagen vascular disease, should be considered. Treatment with an anticoagulant
agent might then be appropriate.
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Thrombocytopenia is often experienced in pregnancy,
affecting up to 10% of all pregnancies [1,2]. Idiopathic
thrombocytopenic purpura (ITP) is a common cause of
thrombocytopenia in the first and second trimesters.
The pathogenesis of ITP is related to the production of
anti-platelet antibodies, resulting in accelerated clear-
ance and destruction of opsonized platelets by the retic-
uloendothelial system. Because anti-platelet antibodies
also target antigens on megakaryocytes, suppressed
platelet production might be the mechanism causing
thrombocytopenia in ITP [3]. In general, corticosteroids* Correspondence: hisano-m@ncchd.go.jp
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unless otherwise stated.are the first-line treatment for pregnant women with
ITP, and intravenous immunoglobulin (IVIG) is used to
rapidly raise the platelet count [4-6]. The use of rituxi-
mab and thrombopoietic agents during pregnancy for
ITP has been avoided because of limited information on
their safety and clinical effects. In our ITP case, com-
bined treatment with an anticoagulant agent from the
early weeks of pregnancy was useful for reducing the
progression of thrombocytopenia.Case presentation
A 28-year-old woman with ITP visited our hospital with
the desire to have children. ITP had been already diag-
nosed by a prior history of bleeding and a low platelet
count, and other possible causes of thrombocytopenia
were excluded based on physical and bone marrowThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vere thrombocytopenia. She had a platelet count of 3 ×
109/L and subcutaneous bleeding immediately following
pregnancy at 6 weeks’ gestation, despite maintaining the
platelet count at 30–90 × 109/L with 3–5 mg/day of
prednisolone (PSL) before pregnancy. The patient’s
platelet count could not be maintained at higher than
30 × 109/L, even with two treatments of IVIG (0.4 g/kg/
day for 5 days) and intravenous pulses of methylprednis-
olone (0.5 g/day for 4 days) followed by oral PSL
(30 mg/day). Her attending physician decided to end her
pregnancy with platelet transfusion for reasons of maternal
safety at 10 weeks’ gestation. To ensure subsequent
pregnancies, we controlled the platelet count at pre-
pregnancy at a set point of higher than 100 × 109/L
with 17.5 mg/day of PSL. The patient then became
pregnant for the second time.
Initial laboratory studies at the first visit after preg-
nancy showed a white blood cell count of 4.83 × 109/L,
hemoglobin of 140 g/L, mild thrombocytopenia with a
platelet count of 70 × 109/L, and high levels of fibrinogen
degradation products (FDP) (4.3 μg/mL; normal range,
<4) and D-dimer (2.9 μg/mL; normal range, <1). The re-
sults of other blood coagulation tests were as follows:
prothrombin time/international normalized ratio of 0.96,
activated partial thromboplastin time of 23.4 s, fibrino-
gen level of 2.56 g/L, antithrombin III activity of 92.1%,
protein C activity of 89% (normal range, 64–146%), pro-
tein C antigen level of 81% (normal range, 70–150%),
protein S activity of 52% (normal range, 60–150%), pro-
tein S antigen level of 75% (normal range, 65–135%),
and platelet factor 4 (PF-4) level of 8 ng/mL (normal
range, <20 ng/mL). Immunological analysis showed a
weakly positive antinuclear antibody titer of 1:80, anti-
DNA antibody was 2.0 IU/mL (normal range, <6 IU/
mL), anti-U1-RNP antibody was 121 U/mL (normal
range, <10 IU/mL), CH50 was 45.1 U/mL, C3 was
84 mg/dL, C4 was 24 mg/dL, and platelet-associated IgGFigure 1 Clinical course. a Changes in platelet count and levels of FDP, D-d
(10,000 U/day). b Medications and changes in platelet count and PA-IgG valu(PA-IgG) was 59 ng/107cells (normal range, <46
ng/107cells). Lupus anticoagulant was 1.03 (normal
range, <1.3) and antiphospholipid antibodies, including
anti-cardiolipin IgG antibodies, anti-β2-glycoprotein I
antibodies, and anti-prothrombin antibodies, were not
detected. Immediately following pregnancy, an elevation
in FDP and D-dimer levels, with a decrease in platelets
was observed (Figure 1a). Thrombocytopenia and a
fibrinolytic state became significant with the date of ges-
tation and the level of PF-4 was increased (127 ng/mL)
at 9 weeks’ gestation. This suggested that a rapid de-
crease in platelet count after pregnancy might be associ-
ated with platelet activation and thrombogenesis, as well
as with antibody-mediated destruction of platelets. Our
patient had no clinical evidence of arterial and venous
thrombosis. No significant aberrations in platelet aggre-
gation tests (collagen, 67%; ristocetin, 78%; epinephrine,
68%; adenosine diphosphate, 70%), von Willebrand factor
antigen level (362%; normal range, 20–155%), von Willeb-
rand factor activity (388%; normal range, 60–170%),
ADAM13 activity (158%; normal range, 70–120%), and
factor VIII activity (200%; normal range, 62–145%) were
observed. Anticoagulation therapy was performed by con-
tinuous unfractionated heparin injection (10,000 U/day),
and the dose of PSL was increased to 30 mg/day at
10 weeks’ gestation. We used additional IVIG (0.4 g/kg/
day for 5 days), albeit early in the course of the disease,
and also expected to minimize the dose of corticosteroids
in the first trimester. The platelet count recovered from
40 × 109 /L to 90 × 109 /L for 3 weeks. The laboratory find-
ings in the second trimester were as follows: PA-IgG was
32 ng/107cells, platelet antibody-secreting B cells for
GPIIb/IIIa antigen by ELISPOT assay was 2.3 × 106 cells/
mL (normal range, <2.0 × 106 cells/mL), the reticuloplate-
let ratio was 3.7% (normal range, 0.7–3.0%), thrombopoie-
tin was 0.44 pg/mL (normal range, <300 pg/mL), and PF-4
was 13 ng/mL. The dose of PSL was tapered below 15 mg
daily and heparin treatment was continued throughoutimer, and PF-4 before and after treatment with unfractionated heparin
es in the pregnant and puerperal periods.
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100 × 109/L (Figure 1b), and she delivered a 2500-g boy
vaginally at 37 weeks’ gestation without any hemorrhage.
Infant Apgar scores were 9 and 10 at 1 and 5 min, respect-
ively. Neonatal thrombocytopenia secondary to maternal
ITP did not occur.
Conclusions
The causes of pregnancy-specific thrombocytopenia are
gestational thrombocytopenia, pre-eclampsia, HELLP
syndrome, and acute fatty liver of pregnancy [1,2]. Ges-
tational thrombocytopenia, which is the most common
cause of thrombocytopenia in pregnancy (approximately
75% of cases), may be difficult to differentiate from ITP.
However, gestational thrombocytopenia generally causes
mild thrombocytopenia, usually >70 × 109/L, from the
mid-second or third trimester, and is not related to ad-
verse events for the mother and newborn. In some cases,
pregnancy might lead to worsening of thrombocytopenia
in patients with ITP [4]. This may be caused by the
effects of the hormonal milieu of pregnancy on the retic-
uloendothelial system, similar to those reported in auto-
immune hemolytic anemia [7]. In our case, moderate
thrombocytopenia appeared immediately following preg-
nancy. Therefore, we were concerned that the patient
might become seriously ill again. The differences be-
tween a typical ITP course and that in the current pa-
tient with ITP were her laboratory findings, which were
suggestive of a thrombogenic state; elevation of markers
of intravascular coagulation; and platelet activation (FDP,
D-dimer, and PF-4). The patient did not have any under-
lying disease that could be associated with disseminated
intravascular coagulation. Overt disseminated intravas-
cular coagulation scoring proposed by the International
Society of Thrombosis and Hemostasis was 4 points.
Antiphospholipid syndrome is a disorder that occurs
with exacerbation in association with pregnancy, and is
known to cause arterial and venous thrombosis,
thrombocytopenia, complications in pregnancy (mis-
carriage, fetal loss, and pre-eclampsia), and livedo reti-
cularis [8]. Antiphospholipid antibodies, especially
anti-cardiolipin antibodies, anti-β2-glycoprotein I anti-
bodies, and lupus anticoagulant, are associated with
antiphospholipid syndrome, which is often observed in
patients with systemic lupus erythematosus. In our
case, antiphospholipid antibody and anti-DNA antibody
were negative, but anti-U1-RNP antibody, characteristic of
mixed connective tissue disease, and weakly positive anti-
nuclear antibody were detected. However, the patient did
not have clinical findings that suggested the presence of
mixed connective tissue disease, including Raynaud
phenomenon, swollen hands or puffy fingers, arthritis,
myositis, and pulmonary involvement. We consider that
the cause of thrombocytopenia in this patient may havebeen due to antibody-mediated destruction of platelets, as
well as platelet activation and consumption following
microvascular injury and thrombogenesis. In a previous
pregnancy in our patient, artificial abortion had to be
chosen because of severe thrombocytopenia, despite two
treatments of IVIG and high doses of corticosteroids.
Anticoagulant therapy using unfractionated heparin
(10,000 U/day) helped to inhibit the progression of a de-
crease in platelet count and the dose of corticosteroids
was reduced during pregnancy this time. Although we
considered that it was reasonable to use aspirin as an anti-
platelet agent for our patient’s clinical condition, in the
event that thrombocytopenia became more severe, the pa-
tient would be at high risk for bleeding. We found it diffi-
cult to decide how long heparin treatment should be
continued during pregnancy. The underlying causes lead-
ing to the series in our patient’s pregnancy course are un-
certain. However, considering her laboratory findings,
such as rapidly developing thrombocytopenia and a
fibrinolytic state in the first trimester that manifested as
antiphospholipid syndrome, we continued heparin treat-
ment to prevent fetal loss in later pregnancy and maternal
complications, such as thrombosis, preeclampsia, and
HELLP syndrome. Notably, we also observed serological
abnormalities, such as weakly positive antinuclear anti-
body and anti-U1-RNP antibody. Although clinical mani-
festations suggestive of collagen vascular disease have not
appeared to date, we will continue to follow this patient.
When thrombocytopenia rapidly develops in a patient
with ITP immediately following pregnancy, and micro-
vascular injury and thrombogenesis are suspected,
markers of intravascular coagulation and platelet activa-
tion should be measured and collagen vascular disease
should be screened for. Use of an anticoagulant agent
might then be appropriate.
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